Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective Observational PK/PD Study of Venetoclax in AML and High-Risk MDS
ChiCTR2200061294Phase 4Not yet recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of venetoclax in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoint: Pharmacokinetics of venetoclax. Planned start Jun 2022; status: not yet recruiting.
02
Drugs
venetoclax
03
Conditions
acute myeloid leukemia (AML)myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on ChiCTR2200061294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200061294.